An estrone (E1) test measures an estrogen produced in the ovaries, adrenal-related pathways, and especially through conversion of androgens in fat and other tissues. Estrone is less potent than estradiol but becomes the relatively dominant circulating estrogen after menopause. The test is not routinely needed for typical menopause symptoms, because menstrual history and symptoms usually provide more useful information. It may be ordered when an estrogen source is unclear, when a postmenopausal or male estrogen result is unusual, or when a clinician is monitoring selected hormone treatments or estrogen-producing conditions. High estrone can occur with obesity, estrogen therapy, liver disease, or rarely an ovarian, testicular, or adrenal tumor. Low estrone is common after menopause and may accompany ovarian or pituitary dysfunction before menopause. Laboratory methods, age, sex, reproductive stage, medicines, and body composition affect the result. Estrone should be interpreted with estradiol, FSH, LH, symptoms, and the exact clinical question.
- Estrone is a weaker estrogen that becomes relatively more prominent after menopause.
- Routine estrone testing is usually unnecessary for diagnosing typical perimenopause or menopause.
- High E1 may reflect peripheral conversion in body fat, estrogen use, liver disease, or a rare hormone-producing tumor.
- Low E1 is expected after menopause but may support ovarian or central dysfunction in younger patients.
- Ranges differ by sex, age, reproductive stage, and assay; estrone and estradiol are not interchangeable.
- Postmenopausal bleeding or rapid estrogen-related changes require clinical evaluation even with a normal result.
Table of Contents
- What the estrone Test Measures
- Why the Test Is Ordered
- Preparation, Timing, and the Testing Process
- Normal Range and How Results Are Interpreted
- What High estrone Results Can Mean
- What Low estrone Results Can Mean
- How Results Fit With Other Hormones and Tests
- Next Steps After the Result
What the estrone Test Measures
Estrone is formed directly in the ovaries and by aromatization of androstenedione in adipose tissue, muscle, skin, and other sites. It can be converted to estradiol and stored as estrone sulfate, creating a reservoir that contributes to estrogen exposure.
Before menopause, estradiol generally dominates ovarian estrogen activity. After ovarian follicle activity declines, peripheral conversion becomes a larger proportion of total estrogen production, making estrone relatively more prominent even though absolute levels are lower than reproductive-age estradiol peaks.
A hormone result is a measurement made under defined laboratory conditions, not a diagnosis by itself. The same concentration can carry different meaning at different ages, cycle stages, pregnancy stages, or times of day. Laboratories also use different analyzers, calibration systems, antibodies, and calculation methods. For that reason, the reference interval printed beside the result should take priority over a range copied from another report or website.
Estrone is not a direct measure of “estrogen balance.” The clinical effect depends on receptor exposure, conversion between estrogens, treatment, metabolism, and tissue sensitivity. A single serum value cannot quantify lifetime estrogen exposure.
The estrogen levels test compares E1 with E2 and E3 across reproductive stages.
Why the Test Is Ordered
Estrone is a targeted test. It is ordered when knowing this specific estrogen fraction could clarify an unexpected estrogen pattern.
- Unexpected estrogen elevation after menopause.
- Gynecomastia or estrogen excess in men when estradiol does not fully explain the pattern.
- Selected monitoring of estrogen therapy or a known estrogen-producing tumor.
- Evaluation of rare steroid-metabolism conditions.
- Research or specialist assessment of peripheral estrogen production.
- Clarifying a total-estrogen result that may include multiple compounds.
Estrone is not a standard ovarian reserve test and does not predict natural fertility. It also does not replace endometrial evaluation for postmenopausal bleeding. When menopause occurs at the usual age, repeated E1 or E2 testing rarely changes symptom treatment.
Interpretation starts with the reason the test was ordered. A clinician looking for an adrenal enzyme disorder uses different cutoffs and follow-up tests than a clinician evaluating irregular periods, infertility, menopausal symptoms, or androgen deficiency. The result should be read with symptoms, examination findings, age, reproductive stage, and related laboratory values rather than compared with one universal “optimal” number.
For typical menopause questions, a menopause hormone evaluation should be used selectively rather than as routine screening.
Preparation, Timing, and the Testing Process
Timing is less cycle-dependent than for progesterone, but reproductive stage, treatment timing, and the reason for testing should be documented.
- Confirm the order is for estrone, not estradiol or total estrogens.
- Record menstrual status, last period, pregnancy possibility, and menopause stage.
- List oral, transdermal, injectable, vaginal, compounded, or over-the-counter hormone products.
- Note liver disease, major weight change, and medicines that affect steroid metabolism.
- Use the same laboratory and method for serial monitoring when possible.
Oral estrogens undergo first-pass liver metabolism and may produce different estrone-to-estradiol patterns from transdermal preparations. The interval from the last dose can affect a treatment-monitoring result. Fasting is usually not required unless other tests do.
Before collection, provide a complete list of prescription medicines, over-the-counter products, supplements, contraceptives, fertility drugs, and hormone therapy. Do not stop prescribed treatment without instructions. Some products change hormone production, while others alter binding proteins or interfere with an immunoassay. High-dose biotin is a well-known source of interference in several hormone tests, although the direction and size of the error depend on the platform.
Acute illness can temporarily suppress or stimulate reproductive signaling. A test drawn during fever, major surgery, severe calorie restriction, or intense training may describe that temporary state rather than the person’s usual hormone function. When the clinical situation is stable and there is no urgent reason to test immediately, postponing or repeating the measurement can prevent an incorrect label.
Normal Range and How Results Are Interpreted
Estrone is usually reported in pg/mL or pmol/L. Ranges vary substantially, especially at low postmenopausal and male concentrations.
| Context | Expected pattern | Interpretive caution |
|---|---|---|
| Reproductive-age cycling | Variable ovarian and peripheral contribution | Cycle stage and E2 matter |
| Postmenopause without therapy | Lower absolute level; E1 relatively dominant | Sensitive assay may be needed |
| Oral estrogen therapy | E1 may rise disproportionately | Do not apply untreated ranges |
| Higher body fat | Greater peripheral aromatization may occur | Not diagnostic by itself |
| Male or pediatric testing | Low concentrations | Method accuracy is especially important |
A laboratory reference interval describes its method and comparison population. A value near the upper limit after menopause is not automatically dangerous, and a low value is not automatically a treatment indication. Symptoms and the reason for testing determine relevance.
A value close to a cutoff deserves more caution than a value that is clearly and repeatedly abnormal. Borderline results may move across the reference limit because of normal biologic variation, recent illness, sleep disruption, exercise, stress, or sample timing. Clinicians often repeat a test under better-controlled conditions before ordering imaging or beginning treatment. The repeat is most useful when the timing, medication list, and assay method are documented.
Trends can be useful when the same question is followed over time, but only when the measurements are reasonably comparable. A change between laboratories may reflect a method difference. A change after starting or stopping hormones may be expected. Record the laboratory, units, collection time, cycle day or pregnancy week, and relevant treatment so later results can be compared in context.
Estradiol remains the more common marker for ovarian function; see the E2 test for cycle-specific interpretation.
What High estrone Results Can Mean
High estrone can result from increased production, external estrogen exposure, reduced metabolism, or an inappropriate reference comparison.
- Oral estrogen therapy or other estrogen-containing medication.
- Increased peripheral conversion of androgens, often associated with higher adipose mass.
- Liver disease affecting hormone metabolism.
- Normal reproductive-cycle or pregnancy-related estrogen production when the wrong interval is used.
- Rare estrogen-producing ovarian, testicular, or adrenal tumors.
- Assay interference or a total-estrogen result mistaken for estrone.
In postmenopausal patients, persistent unexpected elevation is reviewed with estradiol, medications, liver function, and symptoms. Imaging is not automatic; it is more appropriate when the biochemical pattern is confirmed or when bleeding, a mass, or other concerning findings are present.
In men, estrogen-related symptoms may reflect the ratio of androgen to estrogen rather than estrone alone. Testosterone deficiency, obesity, liver disease, medicines, and hCG-related conditions can contribute and require broader assessment.
Confirm the exact product and route of any hormone therapy before labeling a result abnormal. Postmenopausal bleeding needs direct evaluation of the uterus regardless of the E1 level.
When testosterone and estrogen appear discordant, a testosterone blood test and SHBG can clarify the pattern.
What Low estrone Results Can Mean
Low estrone is expected after menopause and may be normal in men or children. Before menopause, it can accompany reduced ovarian or central reproductive signaling.
- Natural menopause.
- Primary ovarian insufficiency or ovarian damage.
- Hypothalamic or pituitary suppression.
- Very low body fat or severe energy deficiency.
- Aromatase inhibition or other estrogen-suppressing treatment.
- Normal low concentration for the person’s sex, age, or life stage.
Low E1 alone does not identify the level of dysfunction. FSH, LH, and estradiol are usually better for distinguishing ovarian failure from central suppression. Bone health, menstrual pattern, hot flashes, vaginal symptoms, and age guide whether treatment is appropriate.
Trying to raise estrone specifically is not a standard treatment goal. When hormone therapy is indicated, the product and dose are selected for symptoms, bone protection, reproductive development, or another defined outcome.
In a younger person with absent periods or estrogen-deficiency symptoms, evaluate pregnancy, FSH, LH, estradiol, prolactin, thyroid function, nutrition, and chronic disease. A low result after menopause usually needs no action by itself.
Persistent estrogen deficiency before age 40 may warrant a primary ovarian insufficiency panel.
How Results Fit With Other Hormones and Tests
Estrone should be read alongside estradiol and gonadotropins because the ratio and life stage often explain the result.
| E1 pattern | Related findings | Possible explanation |
|---|---|---|
| High E1 on oral estrogen | E2 variable; SHBG may be high | Expected first-pass metabolism effect |
| High E1 after menopause | E2 high or symptoms present | External estrogen, peripheral conversion, liver issue, or rare source |
| Low E1 + high FSH | E2 also low | Ovarian insufficiency or menopause |
| Low E1 + low/normal FSH | E2 low | Central or functional suppression |
| E1 and E2 disagree markedly | Clinical picture does not fit | Check assay, units, and treatment |
Estrone sulfate is not the same measurement as estrone, and “total estrogens” may include multiple metabolites. Confirming the analyte prevents comparisons between tests that were never intended to match.
Next Steps After the Result
The next step is usually to verify why E1 was ordered and whether a more direct test would answer the clinical question.
- Confirm the analyte, units, assay, age and sex interval, and reproductive stage.
- Review every estrogen-containing product and the route and timing of use.
- Repeat an unexpected result with estradiol and related hormones when appropriate.
- Assess bleeding or masses directly instead of relying on serum estrogen.
- Use liver, thyroid, gonadotropin, or imaging studies only when the pattern supports them.
- Treat the underlying condition or symptoms rather than targeting E1 alone.
For menopause, symptom management may involve nonhormonal options or menopausal hormone therapy after a risk assessment. For younger patients with ovarian insufficiency, hormone replacement often serves a different purpose and duration. These decisions should not be based on an isolated estrone value.
Bring the actual report to the follow-up visit rather than only recalling that the level was “high” or “low.” The report shows units, the laboratory interval, specimen type, and sometimes the assay method. Ask whether the result needs confirmation, whether a related hormone should be measured at the same time, and what finding would change management.
A useful plan defines the next step and its timing. That may be no action, a repeat test, a dynamic stimulation or suppression test, ultrasound, semen analysis, genetic testing, or referral to endocrinology, reproductive endocrinology, urology, or maternal-fetal medicine. It should also identify symptoms that warrant earlier contact instead of waiting for the routine appointment.
Rapidly progressive symptoms deserve faster evaluation than a mild, stable laboratory abnormality. Examples include sudden virilization, severe headache with visual change, signs of adrenal crisis, heavy bleeding with dizziness, or concerning pregnancy symptoms. The laboratory number may guide the workup, but urgent decisions are driven by the whole clinical picture.
Treatment should address the confirmed cause and the person’s goals. Lowering or raising a laboratory value without establishing why it is abnormal can hide an important condition or create new problems. Hormone therapy can affect fertility, blood counts, liver function, clot risk, bone health, and pregnancy, so monitoring plans should be individualized.
Postmenopausal bleeding, heavy bleeding with faintness, a new pelvic or testicular mass, or severe abdominal pain needs prompt clinical assessment. A normal estrone result does not rule out a serious cause.
When a repeat measurement is planned, try to reproduce the conditions that matter for this test. Use the same laboratory when practical, note the collection time, and record any change in medicines or reproductive stage. Consistency does not remove all biologic variation, but it makes a true trend easier to distinguish from noise.
Reference intervals describe a population selected by the laboratory; they do not define a treatment target for every person. A result inside the interval can still require attention when symptoms are strong or when another hormone shows a clear mismatch. Conversely, a small deviation may not represent disease when the timing or clinical setting explains it.
A laboratory result can answer only the question built into the test. It may show hormone concentration, but it cannot by itself prove ovulation quality, egg quality, sperm production, placental health, or the cause of a symptom. Those conclusions usually require a combination of history, examination, imaging, and other targeted tests.
When fertility is the concern, age, duration of trying to conceive, menstrual pattern, pregnancy history, semen findings, and tubal or uterine factors often affect the plan as much as a single hormone value. Testing both partners in parallel can prevent months of delay and reduce the chance that an incidental hormone result distracts from a more direct cause.
When symptoms are being monitored rather than fertility, define the outcome that treatment is meant to improve. Examples include restoration of periods, relief of hot flashes, reduction of unwanted hair growth, recovery of sexual function, preservation of bone health, or safe progression of puberty. Laboratory monitoring is most useful when tied to one of these clinical outcomes.
People using nonprescription “hormone balance” products should mention them before testing. DHEA, progesterone creams, testosterone boosters, compounded preparations, and biotin can alter physiology or make results harder to interpret. Product labels may not reliably predict the dose absorbed, so the safest approach is to review the exact container or ingredient list with the clinician.
Results can also differ because laboratories report conventional and SI units. A value expressed in ng/dL cannot be compared directly with one expressed in nmol/L without a hormone-specific conversion. Always compare the number, unit, and interval together. This simple check prevents many apparent contradictions between reports.
An abnormal result can have emotional weight, especially during fertility treatment, pregnancy, or puberty evaluation. Ask the clinician to separate what is known from what remains uncertain. A clear explanation of the likely causes, the confirmation plan, and the time frame for action is more useful than trying to interpret every decimal place independently.
Clinicians also consider whether the test result agrees with the physical findings. A marked biochemical abnormality without expected symptoms may prompt confirmation with a more specific laboratory method. Strong symptoms with a normal result may lead to testing at a different time, measuring a related hormone, or looking for a nonhormonal cause.
The pace of change can be as important as the level itself. Slow changes over years commonly fit physiologic aging or a chronic endocrine condition. Changes over weeks or a few months raise more concern for a new medicine effect, pregnancy-related change, acute illness, or a hormone-producing lesion, especially when symptoms progress quickly.
No single follow-up pathway fits every abnormal value. Mild and explainable results may only need observation. Persistent or substantial abnormalities may require specialist review and tests chosen to locate the source of hormone production or the level of signaling failure. The sequence should be deliberate so that each test answers a specific unresolved question.
Keep a copy of the laboratory report and the order indication. The clinician needs more than the highlighted flag: the numeric value, unit, reference interval, specimen type, collection date and time, and any comment about the assay can change interpretation. A result copied into a patient portal message without those details may be impossible to compare with a later test. This documentation is especially important when care moves between a primary clinician, endocrinologist, fertility clinic, and hospital laboratory.
Before repeating testing, decide what the repeat is meant to resolve. It may confirm persistence, correct a timing error, remove a medication effect, or use a more specific assay. Repeating the same poorly timed test without changing the conditions often reproduces uncertainty rather than solving it. The clinician should also state what result would lead to observation, another laboratory test, imaging, or treatment.
Small deviations from a reference interval are common because the interval usually contains about 95% of a selected comparison population. Some healthy people fall outside it, while some people with disease fall inside it. The clinical importance depends on how far the value is from the limit, whether it persists, whether related hormones agree, and whether symptoms fit the physiology. A reference flag is therefore a prompt for interpretation, not proof of disease.
Hormone results are also affected by changes in binding proteins and metabolism. Liver disease, thyroid disease, kidney disease, pregnancy, body composition, and oral estrogen exposure can change measured concentrations without producing the same change in tissue effect. When a binding issue is suspected, the clinician may use a free or calculated hormone, a related binding protein, or a more specific laboratory method rather than interpreting the total concentration alone.
Fertility decisions should not be reduced to a single endocrine value. A hormone may help choose medication dose, confirm ovulation, or identify a treatable disorder, but it does not measure every step required for pregnancy. Reproductive age, sperm exposure or semen quality, tubal patency, uterine anatomy, timing, prior pregnancies, and the duration of trying all influence the next step. A balanced evaluation prevents overreaction to an incidental result.
Testing can be different during pregnancy, adolescence, menopause, or hormone treatment because physiology is intentionally changing. A range derived from untreated adults may be inappropriate in these settings. Ask whether the laboratory interval matches the patient’s age and reproductive state and whether the clinical team uses a separate treatment or pregnancy target. This is particularly important when a portal automatically marks a result high or low against a generic range.
A laboratory method with greater analytical specificity is useful when the expected concentration is low, the result is surprising, or a major decision depends on the number. Mass-spectrometry methods can separate closely related steroids better than many immunoassays, while dynamic tests can reveal reserve or responsiveness that a basal sample cannot show. The best method depends on the hormone and question; a technically sophisticated test is not automatically necessary for every routine result.
Follow-up intervals should reflect the pace of the suspected condition. A stable borderline value may be repeated after a complete cycle, after recovery from illness, or after a treatment change reaches steady state. Rapidly progressive symptoms require days or weeks rather than months of observation. The plan should state both the routine follow-up date and the symptoms that justify contacting the clinician sooner.
References
- Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQCML/SEEN/SEEP 2023 (Position Statement)
- Comprehensive Review of Estradiol, Progesterone, Luteinizing Hormone, and Follicle-Stimulating Hormone Reference Intervals in Transgender, Nonbinary, and Cisgender Individuals 2025 (Review)
- Menopause 2026 (Review)
- Current evaluation of amenorrhea: a committee opinion 2024 (Committee Opinion)
- Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing 2023 (Review)
Disclaimer
This article is general information and cannot diagnose menopause, ovarian or pituitary disease, or a hormone-producing tumor. Estrone ranges depend on life stage, method, and hormone use. Postmenopausal bleeding requires medical evaluation regardless of the result.
